Phase Ib/II Investigator Initiated Safety and Efficacy Clinical Trial of Combination Therapy of Intracutaneous GEN0101 With Intravenous Pembrolizmub in Patients Who Have Advanced Melanoma
Latest Information Update: 05 Jul 2022
At a glance
- Drugs GEN 0101 (Primary) ; GEN 0101 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 04 Feb 2019 New trial record